Welcome to our dedicated page for Aequus Pharmaceu news (Ticker: AQSZF), a resource for investors and traders seeking the latest updates and insights on Aequus Pharmaceu stock.
Aequus Pharmaceuticals Inc. (OTCQB: AQSZF) is a Canadian specialty pharmaceutical company developing innovative treatments in ophthalmology, transplant care, and rare diseases. This dedicated news hub provides investors and healthcare professionals with essential updates on product developments, regulatory milestones, and strategic partnerships.
Access timely announcements regarding the company's Evolve® product line, including progress on MDSAP certification for Canadian market re-entry. Stay informed about therapeutic advancements across key treatment areas and expansion initiatives through collaborative ventures.
Our curated news collection features official press releases on regulatory submissions, partnership agreements, and corporate developments. Regular updates ensure stakeholders maintain current understanding of Aequus' progress in enhancing patient care through differentiated pharmaceutical solutions.
Bookmark this page for direct access to verified company communications. Check back frequently for the latest information on product availability updates and market expansion strategies within Canada's healthcare sector.
Aequus Pharmaceuticals Inc. (OTCQB: AQSZF) has announced the granting of incentive stock options to directors, officers, employees, and consultants, totaling 2,775,000 common shares. These options will be exercisable at a price of $0.03 per share over a term of eight years and will vest over three years. This move aligns with the Company's stock option plan and the TSX Venture Exchange policies. Aequus is focused on developing and commercializing specialized pharmaceutical products, particularly in ophthalmology and seeks to expand its Canadian platform through internal development or acquisitions.
Aequus Pharmaceuticals (TSX-V: AQS, OTCQB: AQSZF) has secured a $500,000 loan from CEO Doug Janzen to support the launch of Zimed® PF, a new preservative-free treatment for elevated intraocular pressure in glaucoma patients. The loan carries a 2.5% interest rate and is repayable on demand. Zimed® PF received Health Canada approval last December and is the only multi-dose preservative-free prostaglandin analog available, aimed at reducing side effects linked to preservatives. Aequus plans to use the funds for sales efforts, digital resources, and general working capital as it prepares for a critical product launch.
Aequus Pharmaceuticals Inc. (AQSZF) has received approval from Health Canada for Zimed® PF (Bimatoprost 0.03%), a preservative-free treatment for elevated intraocular pressure in patients with open-angled glaucoma and ocular hypertension. This innovative product, which utilizes a unique multi-dose bottle design, aims to improve patient adherence and reduce the risk of ocular surface disease typically associated with preservatives. The launch is set for 2023, with expectations for strong market uptake in Canada.